The clinical benefits of BRAF inhibition in patients with advanced-stage BRAF-mutant
melanoma are now well established. Although the emergence of cutaneous squamous-cell …

Tumor progression relies upon the dynamic interaction of cancer cells with host fibroblasts,
endothelial cells, immune cells and components of the extracellular matrix, collectively …

Emerging data support the rationale of combined therapies in advanced melanoma.
Specifically, the combined use of drugs with different mechanisms of action can reduce the …

Background BRAF-mutant melanoma is characterized by aggressive metastatic potential
and therapeutic resistance. The innate immune receptor RIG-I has emerged as a potential …

Objectives Unlike adults, malignant melanoma in children and adolescents is rare. In adult
melanoma, significant progress in understanding tumor biology and new treatments …

Because of advances in targeted therapies, the clinical evaluation of cutaneous melanoma
is increasingly based on a combination of traditional histopathology and molecular …

Abstract Inhibition of B-Raf/MEK/ERK signaling is an effective therapeutic strategy against
certain types of cancers such as melanoma and thyroid cancer. While demonstrated to be …

Incidence of subsequent malignant tumor development in 740 patients with primary
cutaneous melanoma verified between 2006 and 2010 at the Semmelweis University was …

An estimated 76,100 patients will be diagnosed with invasive melanoma in the United States
in 2014, and 9,710 patients will die from the disease. In almost all cases, the cause of death …

Clinical oncology is a specialty that currently holds a central role in the management of skin
cancer patients, with rising importance in a broad range of settings not limited to metastatic …